Skip to main content
. Author manuscript; available in PMC: 2010 Jul 1.
Published in final edited form as: Clin Endocrinol (Oxf). 2008 Dec 5;71(1):11–17. doi: 10.1111/j.1365-2265.2008.03496.x

Table 3.

Localization of PHEO

[18F]-FDA [123I]-MIBG [123I] or [131I]-MIBG CT MRI
Non-metastatic PHEO, per lesion analysis
Sensitivity 78% (25/32) 78% (21/27) 76% (22/29) 97% (31/32) 92% (24/26)
Specificity 77% (10/13) 92% (12/13) 92% (12/13) 38% (5/13) * 58% (7/12)
Metastatic PHEO, per patient analysis
Sensitivity 97% (33/34) 85% (17/20) 65% (20/31) # 100% (32/32) 100% (31/31)
*

P=0.039 versus [123I], and [123]/[131] MIBG

#

P=0.002 versus [18F]-FDA, whole body CT, and whole body MRI